The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2015

Filed:

Apr. 13, 2009
Applicants:

Philip Tan, Edmonds, WA (US);

Sandy a Simon, Seattle, WA (US);

Charles G Cerveny, Seattle, WA (US);

Christy Anne Nilsson, Sammamish, WA (US);

William Brady, Bothell, WA (US);

Jeffrey a Ledbetter, Shoreline, WA (US);

Martha S Hayden-ledbetter, Shoreline, WA (US);

Peter a Thompson, Bellevue, WA (US);

Cecile Morales, Seattle, WA (US);

Inventors:

Philip Tan, Edmonds, WA (US);

Sandy A Simon, Seattle, WA (US);

Charles G Cerveny, Seattle, WA (US);

Christy Anne Nilsson, Sammamish, WA (US);

William Brady, Bothell, WA (US);

Jeffrey A Ledbetter, Shoreline, WA (US);

Martha S Hayden-Ledbetter, Shoreline, WA (US);

Peter A Thompson, Bellevue, WA (US);

Cecile Morales, Seattle, WA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 31/4184 (2006.01); C07K 16/46 (2006.01); A61K 38/16 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39541 (2013.01); A61K 31/4184 (2013.01); A61K 38/16 (2013.01); A61K 39/39558 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); C07K 16/461 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/50 (2013.01);
Abstract

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.


Find Patent Forward Citations

Loading…